Edition:
India

Tata Consultancy Services Ltd (TCS.NS)

TCS.NS on National Stock Exchange of India

2,419.00INR
3:08pm IST
Change (% chg)

Rs-3.30 (-0.14%)
Prev Close
Rs2,422.30
Open
Rs2,440.00
Day's High
Rs2,440.00
Day's Low
Rs2,366.00
Volume
3,857,976
Avg. Vol
4,083,692
52-wk High
Rs2,555.00
52-wk Low
Rs1,506.05

Select another date:

Thu, Sep 24 2020

Indian shares fall; slides in TCS, ONGC weigh

BENGALURU, Sept 24 Indian shares fell for a sixth straight session on Thursday, dragged by sharp declines at Tata Consultancy Services following a shareholder spat at its parent group and Oil and Natural Gas Corp after a fire broke out at its unit.

BUZZ-Indian IT sector hits record high on strong outlook from HCL Technologies

** India's IT services subindex on the NSE rises as much as 3.4% to hit a record high of 19,257 points, after strong Q2 outlook from HCL Technologies lifts sentiment across the sector

TCS profit misses estimates, pandemic hits client spending

BENGALURU Indian software company Tata Consultancy Services Ltd (TCS) posted a near 14% drop in first-quarter profit on Thursday, that also missed estimates, as the COVID-19 pandemic forced its clients to cut spending on IT services.

UPDATE 1-India's TCS profit misses estimates, pandemic hits client spending

BENGALURU, July 9 Indian software company Tata Consultancy Services Ltd (TCS) posted a near 14% drop in first-quarter profit on Thursday, that also missed estimates, as the COVID-19 pandemic forced its clients to cut spending on IT services.

India's TCS Q1 profit falls 14%, misses estimates on virus hit

BENGALURU, July 9 Indian software behemoth Tata Consultancy Services Ltd (TCS) reported a lower first-quarter profit on Thursday, missing estimates, as the COVID-19 pandemic forced its clients to cut spending on IT services.

BRIEF-Tata Consultancy Services Says Location Independent Way Of Working Gaining Traction

* SAYS REVENUE IMPACT OF COVID-19 PANDEMIC IN QUARTER PLAYED OUT BROADLY ALONG LINES CO HAD ANTICIPATED AT START OF QUARTER

BRIEF-India's TCS Gets Letter From Markets Regulator Warning On Disclosures

* GETS LETTER FROM MARKETS REGULATOR WARNING CO TO BE CAREFUL WITH DISCLOSURES

BRIEF-Sanofi: FDA Grants Approval For Dupixent (dupilumab)

* SANOFI: FDA APPROVES DUPIXENT® (DUPILUMAB) AS FIRST BIOLOGIC MEDICINE FOR CHILDREN AGED 6 TO 11 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS

BRIEF-Tata Consultancy Services Says Managerial Remuneration For FY20 Down By 15%

* DIRECTORS DECIDED TO MODERATE EXECUTIVE REMUNERATION FOR FY 20 TO CONSERVE RESOURCES

Infosys suspends FY revenue forecast on coronavirus blow

(This April 20 story corrects company name to TCS in the fourth paragraph)

Select another date: